Crossmark

Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model

Crossref DOI link: https://doi.org/10.1186/s13027-021-00346-7

Published Online: 2021-01-26

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dorostkar, Fariba

Arashkia, Arash

Roohvand, Farzin

Shoja, Zabihollah

Navari, Mohsen

Mashhadi Abolghasem Shirazi, Maryam

Shahosseini, Zahra

Farahmand, Mohammad

Shams nosrati, Mohammad Sadegh

Jalilvand, Somayeh
Funding

Funding for this research was provided by:

Tehran University of Medical Sciences and Health Services (34892)

Tehran University of Medical Sciences and Health Services (240.293)
License Information

Text and Data Mining valid from 2021-01-26

Version of Record valid from 2021-01-26
More Information

Article History

Received: 1 October 2020

Accepted: 19 January 2021

First Online: 26 January 2021

Ethics approval

: All experiments were performed according to the Helsinki guidelines. The ethic to work on mice was approved by the Local Ethics Committee of Tehran University of Medical Sciences.

: The manuscript was approved for publication by all authors.

: The authors declare that they have no conflict of interests.

Document is current

Any future updates will be listed below